Corporate Finance
Cardiff Oncology faces potential $500M+ valuation hit as pivotal cancer trial data looms
ViaNews Editorial Team (Finance)•
#FDA approval
3 articles
Pharmaceutical Investment Risk
Protara Therapeutics Faces 70% Clinical Trial Failure Risk on TARA-002 Bladder Cancer Drug
ViaNews Editorial Team (Finance)•
Pharma & Biotech
Cellectis Eyes 2028 FDA Filing for Lasme-cel as Cash Runway Extends to Mid-2027
ViaNews Editorial Team (Finance)•